
RealRate

PHARMACEUTICAL 2018

CUMBERLAND PHARMACEUTICALS SPHARMACEUTICALS INC Rank 102 of 342





RealRate

PHARMACEUTICAL 2018

CUMBERLAND PHARMACEUTICALS SPHARMACEUTICALS INC

Rank 102 of 342

The relative strengths and weaknesses of CUMBERLAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CUMBERLAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 64% points. The greatest weakness of CUMBERLAND PHARMACEUTICALS INC is the variable Other Expenses, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 121% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	68,685
Cost of Goods Sold	0
Intangible Assets	21,445
Liabilities, Current	17,695
Liabilities, Non-Current	1,816
Other Assets	2,574
Other Compr. Net Income	0
Other Expenses	35,568
Other Liabilities	9,800
Other Net Income	299
Other Revenues	41,150
Property and Equipment	529
Research and Development	3,901
Selling, General and Administrative Expense	10,030

Output Variable	Value in 1000 USD
Assets	93,232
Liabilities	29,311
Expenses	49,499
Revenues	41,150
Stockholders Equity	63,922
Net Income	-8,050
Comprehensive Net Income	-8,050
Economic Capital Ratio	166%

